Association between polymorphism rs11200638 in the HTRA1 gene and the response to anti-VEGF treatment of exudative AMD: a meta-analysis

Ya-li Zhou, Chun-li Chen, Yi-xiao Wang, Yao Tong, Xiao-ling Fang, Lin Li and Zhao-yang Wang

Abstract

Background: Anti-angiogenesis treatments are the most commonly used treatments for the vision loss caused by exudative age-related macular degeneration (AMD), in which the anti-vascular endothelial growth factor (VEGF) drugs with ranibizumab and bevacizumab are current standard treatments. However, the outcome of anti-VEGF therapeutics is not uniform in all patients.

Methods: We performed a literature-based meta-analysis including five published studies relevant to HTRA1 and response to anti-VEGF treatment (bevacizumab or ranibizumab). Summary odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using fixed- and random-effects models. Sensitivity analysis and meta-regression were also performed. Q-statistic test and Egger’s test was used to evaluate heterogeneity and publication bias respectively.

Results: Overall, no association between the rs11200638 polymorphism in HTRA1 gene and the anti-VEGF treatment response was found in the genotype GG versus AA (OR = 1.06; 95% CI: 0.77 to 1.48; P = 0.98), genotype GA versus AA (OR = 1.11; 95% CI: 0.83 to 1.47; P = 0.93), genotype GG + GA versus AA (OR = 1.22; 95% CI: 0.94 to 1.57; P = 0.09), and allele G versus A (OR = 0.92; 95% CI: 0.78 to 1.08; P = 0.14). In the subgroup analysis by ethnicity Caucasian population, and a significant association was still not observed in all genetic models. Sensitivity analysis indicated the robustness of our findings, and no publication bias was observed in our meta-analysis.

Conclusions: This study shows that there was no association between the polymorphism rs11200638 in HTRA1 gene and response to anti-VEGF treatment of exudative AMD. However, more studies are needed to further prove the conclusion of present study, especially well-designed and high quality randomised controlled trials or intervention studies.

Keywords: Anti-VEGF, Exudative AMD, HTRA1 gene, Treatment response

Background

Age-related macular degeneration (AMD) is a leading cause of irreversible blindness in older individuals worldwide [1, 2]. AMD can be divided into early and advanced stages, according to the clinical features. There are two main categories of advanced AMD: atrophic AMD (dry AMD) and neovascular AMD (exudative AMD). Both of these conditions result in the loss of central vision, but the majority of severe vision loss occurs in exudative AMD, which is characterized by choroidal neovascularization (CNV) [3, 4]. The exact etiology of AMD is remained unknown despite the major risk factors for AMD including advanced age and smoking, with age being the strongest risk factor. In recent years, multiple studies have confirmed that genetic factors also play a substantial role in the etiology of AMD [5–7], such as single nucleotide polymorphisms (SNPs) in the complement factor H (CFH) [8, 9], age-related maculopathy susceptibility 2 (ARMS2) [10, 11], and high temperature requirement factor A1 (HTRA1)-genes [12]. There is already strong evidence that the rs11200638 polymorphism, located in the HTRA1 promoter region [13], can increase susceptibility to AMD, especially
inhibits transforming growth factor-β (TGF-β) to regulate the development of CNV [17]. In addition, HTRA1 is a member of the HTRA family, which plays a critical role in angiogenesis through transforming growth factor-β (TGF-β) family member [18].

Anti-VEGF treatment with ranibizumab or bevacizumab are current standard treatments for the vision loss caused by CNV [19–21]. However, the outcome of anti-VEGF therapeutics is not uniform in all patients. Research were performed to investigate the associations of genetic variants with different response patterns to determine whether genetic variations could predict treatment response and therefore provide personalized therapy. Studies have shown that CFH, ARMS2, HTRA1, vascular endothelial growth factor A (VEGFA), vascular endothelial growth factor receptor 2 (VEGFR2) are all associated with anti-VEGF treatment outcomes [22–24], meanwhile a few literature-based meta-analyses indicated that CFH and ARMS2 polymorphisms might be associated with treatment response and outcomes in exudative AMD [25, 26].

To date, a few studies have also indicated that rs11200638 in the HTRA1 gene could influence patients’ responses to treatment with anti-VEGF drugs for exudative AMD. However, the treatment effect remains controversial. Some studies have identified significant associations between genetic variants of the rs11200638 polymorphism and patient response [23, 24, 27]. In addition, those studies suggested that the HTRA1 promoter SNP (rs11200638) were associated with a poorer visual outcome for ranibizumab or bevacizumab treatment in neovascular AMD, suggesting strong pharmaco genetic associations with anti-VEGF treatment. However, other study has not found any significant associations between HTRA1 and treatment outcomes among different genotypes [28]. As we know, no systematic reviews or meta-analyses have been published to evaluate the relationship between rs11200638 polymorphisms in the HTRA1 gene and the response to anti-angiogenesis treatment for exudative AMD. Here, we conducted a meta-analysis aiming to combine individual studies and to demonstrate the association more precisely.

Methods
Search strategy and inclusion criteria
This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guidelines [29]. We searched in PubMed, Web of Science, and Embase with no limitations on language. The following combinations of relevant key terms in the article were searched: (HTRA1 OR high temperature requirement factor A1 OR rs11200638 OR HtrA1 OR L56 OR PRSS11) and (macular degeneration OR wet-age related macular degeneration OR neovascular age-related macular degeneration OR AMD) and (VEGF OR vascular endothelial growth factor OR angiogenesis OR ranibizumab OR bevacizumab OR aflibercept). We also checked the reference lists of reviews and original articles by manually searching to check for additional studies not yet included in the above databases. All of the related articles had to be published before Mar 10, 2017.

Only published studies with full text articles were included in this meta-analysis. The inclusion criteria were as follows: (1) studies evaluating the relationship between rs11200638 and treatment response to wet-AMD; (2) independent prospective or retrospective association studies; and (3) studies with sufficient available data to estimate an odds ratio (OR) and its 95% confidence interval (CI). After abstracts were screened, the studies were read entirely to assess their appropriateness for the analysis. Meetings abstracts, case reports, editorial comments, review articles and letters were excluded.

Data extraction and management
Two review authors selected the articles for inclusion independently. (Y.L.Z. and C.L.C.), based on the inclusion criteria. The following variables were extracted from each eligible study: surname of the first author, publication year, study type, ethnicity of the study population (Caucasian or East Asian), genotype distributions, mean age (years), frequency of risk allele A, duration of follow-up (months), treatment and study endpoints. Disagreements between two review authors were adjudicated by a third review author (Y.X.W.).

Quality assessment
Two reviewers (Y.L.Z. and C.L.C.) independently assessed the quality of all eligible studies using the Newcastle-Ottawa Quality Assessment Scale (NOS) [30]. A star system was used to judge the data quality based on three perspectives: patient selection, comparability of groups, and assessment of outcome. A nine-point scale of the NOS (range, 0–9 points) was used for the evaluation. Studies were considered to be of poor quality (scores of less than 4), medium quality (scores of 4–6) and high quality (scores of 7–9). Studies with NOS scores greater than 4 points were included in the final analysis. The quality of each study was awarded stars independently by the same two reviewers.

Statistical analysis
We used the OR as the effective index, which was calculated for each study. To explore the possible associations between HTRA1 and anti-VEGF treatment for executive
AMD, the following four genotype comparisons of ORs and their 95% CIs were calculated in the present meta-analysis: GG versus (vs) AA, GA vs AA, GG + GA vs AA, and allele G vs A. Further subgroup analysis was performed to examine the pharmacogenetic associations in Caucasian ethnic.

Heterogeneity assumptions were checked by the Q-statistic test and the I² statistic [31, 32]. If P < 0.10, heterogeneity was considered statistically significant for the Q-statistic test [32]. I² ranges from 0% to 100%. If the I² value of 0% indicates that heterogeneity does not exist, larger values indicate increasing heterogeneity. We chose fixed-effects models to pool the ORs when there was no heterogeneity among studies. Otherwise, the random-effects model was applied [31, 32]. A sensitivity analysis was performed by removing one study at a time to confirm that the stability of the meta-analysis results was not driven by any single study. Meta-regression was performed to detect the sources of heterogeneity [33]. Funnel plots and Egger’s test were used to detect publication bias (P < 0.05 indicated statistically significant publication bias) [34]. Notably, we did not have to check for departure from Hardy-Weinberg equilibrium (HWE) because all of the subjects in this meta-analysis were patients [35].

All the statistical analyses were pooled using Stata software (Version 12.0, Stata Corporation, College Station, Texas, USA). All of the tests were 2-tailed, and P < 0.05 was considered statistically significant.

Results
Literature search procedures and results
A flow diagram of the search procedure is provided in Fig. 1. The search strategy resulted in 199 relevant articles. After excluding 104 duplicates, 70 titles and abstracts were reviewed, and 25 studies investigated associations between the polymorphism rs11200638 genotypes and response to treatment of exudative age-related macular degeneration were shown to be possibly relevant. Twenty of 25 studies failed to provide original data for OR evaluation or noncomparative studies were excluded. We had tried to contact with authors of original studies for data of odds ratios and continuous variable. Total 20 of them had no response) Five remaining studies were included in the meta-analysis [36–40], including 1570 cases, four of which with relatively small sample sizes, (n = 834) with a mean subject number of 184 (range, 104–273) [36–38, 40], except for the study by Hagstrom et al. [39].

The main characteristics of the eligible studies are listed in Table 1. Four studies were prospective, and one was retrospective. Regarding ethnicity, four of these studies were performed in Caucasians and one in East Asians. Two studies used ranibizumab, while 3 studies used either ranibizumab or bevacizumab. The duration of follow-up ranged from 5 to 24 months. We clarified the definition of positive/negative response. Some studies did not clearly define positive responders or negative responders, but this information could be obtained from the context.
The genotype distributions of rs11200638 for all of the studies are summarized in Table 2. Four studies provided the number of positive responders or negative responders with GG/GA/AA genotypes; one by Abedi et al. focused on the comparison of genotype GG + GA vs AA. Moreover, the frequencies of the variant A allele of rs11200638 among all of the studies ranged from 40.86% to 68.61%, with the exception of the study by Abedi et al., which failed to assess allele and genotype distributions of GA and GG, respectively [38].

In terms of the predictive role of rs11200638 in treatment response with the genotype GG + GA vs AA, one of the five studies showed that the A allele tended to predict a poor response [38, 40], when performing genotype comparisons (GG vs AA, GA vs AA, G vs A) in all studies in which there were no statistically significant associations between response to anti-VEGF therapy and the genotype in both the positive-responder and negative-responder groups.

Quantitative synthesis
We meta-analyzed the five included studies for the pooled associations between treatment response in neovascular AMD and rs11200638 genotypes. The results of all genotype comparisons (five studies for GG + GA vs AA, four studies for GG vs AA, GA vs AA, and G vs A) are shown in Table 3 (GG + GA vs AA: OR = 1.61 [95% CI 0.96 to 2.70], P = 0.07, random model; GG vs AA: OR = 1.16 [95% CI 0.84 to 1.60], P = 0.37, fixed model; GA vs AA: OR = 1.20 [95% CI 0.90 to 1.58], P = 0.21, fixed model; G vs A: OR = 1.04 [95% CI 0.69 to 1.56], P = 0.87, random model; Fig. 2). No significant differences were found in the above analysis. Further subgroup analysis was performed to examine the associations in Caucasian population, but these associations did not attain statistical significance in the analysis (Fig. 3).

Sensitivity analysis and meta-regression
The summary ORs remained stable when removing one study at a time. We concluded that no study absolutely changed the relationship between rs11200638 and treatment response, indicating that the results of the present meta-analysis were relatively robust (Fig. 4).

We used meta regression to analyze the heterogeneity of GG + GA vs AA genotype. In view of the number of included literature was only five, we calculated single factor meta-regression, and the year, number of patience (N), ethnicity and intervention as independent variables (Fig. 5).

Publication bias
Funnel plots and Egger's test were performed to assess the publication bias of the included studies. In this meta-analysis, there were no obvious asymmetries of funnel plots in any genotypic comparison, while no statistically significant publication bias differences were found in the results of Egger’s test (GG + GA vs AA: P = 0.09; GG vs AA: P = 0.149; GA vs AA: P = 0.158; G vs A: P = 0.173).

Table 1 Main characteristics and quality scores of the included studies

| Study (year) | Quality score | Study type | Ethnic | Number of cases | Mean age (years) | Treatment Follow-up (months) | Definition of positive response | Study end points |
|--------------|---------------|------------|--------|-----------------|-----------------|-----------------------------|-------------------------------|-----------------|
| McKibbin (2012) [36] | 7 | Prospective | Caucasian | 104 | 81.5 | RBZ 6 | >5 BCVA letter score gain after 6 months | VA (EDTRS) |
| Orlin (2012) [37] | 7 | Retrospective | Caucasian | 149 | 80.6 | RBZ or BVZ 24 | Improved/unchanged VA ≥ 24 months | VA (Snellen) |
| Abedi (2013) [38] | 7 | Prospective | Caucasian | 210 | 78 | RBZ or BVZ 12 | <15 letters lose after 12 months | VA (EDTRS) |
| Hagstrom (2013) [37] | 7 | Prospective | Caucasian | 834 | 78.5 | RBZ or BVZ 12 | 215 letter gain from baseline | VA (EDTRS) |
| Park (2014) [40] | 8 | Prospective | East Asia | 273 | 69.5 | RBZ 5 | 28 letter gain at 5 months | VA (EDTRS) |

RBZ ranibizumab, BVZ bevacizumab, ETDRS Early treatment diabetic retinopathy study, VA visual acuity

Table 2 Allele and genotype distribution of the rs11200638 polymorphism in studies included in the meta-analysis

| Study (year) | Positive Responders | Frequency (A) (%) | Negative Responders | Frequency (A) (%) |
|--------------|---------------------|-------------------|---------------------|-------------------|
| McKibbin (2012) [36] | GG | 53 | 13 | 30 | 10 | 56/50 | 47.17% |
| Orlin (2012) [37] | GG | 93 | 36 | 38 | 19 | 110/76 | 40.86% |
| Abedi (2013) [38] | GG + AG = 148 | 182 | 34 | NA | 56/21 | 40.86% |
| Hagstrom (2013) [39] | GG + AG = 15 | 251 | 47 | 285/17 | 43.23% |
| Park (2014) [40] | GG | 136 | 19 | 54 | 63 | 92/180 | 48.04% |

NA not available

The genotype distributions of rs11200638 for all of the studies are summarized in Table 2. Four studies provided the number of positive responders or negative responders with GG/GA/AA genotypes; one by Abedi et al. focused on the comparison of genotype GG + GA vs AA. Moreover, the frequencies of the variant A allele of rs11200638 among all of the studies ranged from 40.86% to 68.61%, with the exception of the study by Abedi et al., which failed to assess allele and genotype distributions of GA and GG, respectively [38].

In terms of the predictive role of rs11200638 in treatment response with the genotype GG + GA vs AA, one of the five studies showed that the A allele tended to predict a poor response [38, 40], when performing genotype comparisons (GG vs AA, GA vs AA, G vs A) in all studies in which there were no statistically significant associations between response to anti-VEGF therapy and the genotype in both the positive-responder and negative-responder groups.

Quantitative synthesis
We meta-analyzed the five included studies for the pooled associations between treatment response in neovascular AMD and rs11200638 genotypes. The results of all genotype comparisons (five studies for GG + GA vs AA, four studies for GG vs AA, GA vs AA, and G vs A) are shown in Table 3 (GG + GA vs AA: OR = 1.61 [95% CI 0.96 to 2.70], P = 0.07, random model; GG vs AA: OR = 1.16 [95% CI 0.84 to 1.60], P = 0.37, fixed model; GA vs AA: OR = 1.20 [95% CI 0.90 to 1.58], P = 0.21, fixed model; G vs A: OR = 1.04 [95% CI 0.69 to 1.56], P = 0.87, random model; Fig. 2). No significant differences were found in the above analysis. Further subgroup analysis was performed to examine the associations in Caucasian population, but these associations did not attain statistical significance in the analysis (Fig. 3).

Sensitivity analysis and meta-regression
The summary ORs remained stable when removing one study at a time. We concluded that no study absolutely changed the relationship between rs11200638 and treatment response, indicating that the results of the present meta-analysis were relatively robust (Fig. 4).

We used meta regression to analyze the heterogeneity of GG + GA vs AA genotype. In view of the number of included literature was only five, we calculated single factor meta-regression, and the year, number of patience (N), ethnicity and intervention as independent variables (Fig. 5).

Publication bias
Funnel plots and Egger’s test were performed to assess the publication bias of the included studies. In this meta-analysis, there were no obvious asymmetries of funnel plots in any genotypic comparison, while no statistically significant publication bias differences were found in the results of Egger’s test (GG + GA vs AA: P = 0.09; GG vs AA: P = 0.149; GA vs AA: P = 0.158; G vs A: P = 0.173).
Discussion

Age-related macular degeneration is the leading cause of irreversible blindness in older individuals worldwide, especially the exudative type of AMD. Anti-VEGF treatment is currently the standard treatment for vision loss caused by exudative AMD [19–21]. Our study was based on a total of 4 cohort and 1 case-control studies involving 1570 cases to explore the associations between polymorphism rs11200638 in the HTRA1 gene and the response to treatment of exudative AMD specifically. However, both meta-analysis, focusing on the overall population, and the subgroup analysis by Caucasian ethnicity indicated that no statistically pharmacogenetic associations were found between the rs11200638 polymorphism and anti-VEGF treatment outcomes, with no evidence of publication bias. However, there has been strong evidence that the rs11200638 polymorphism can increase

Table 3 Subgroup and overall analysis for the association between genetic effects of rs11200638 polymorphism and anti-angiogenesis treatment of exudative AMD

| Polymorphism | Subgroup   | Study(n) | OR (95% CI) | P Value | P Value | I²% |
|--------------|------------|----------|-------------|---------|---------|-----|
| GG + GA vs AA| Ethnic     | Caucasian | 4           | 1.4 (0.81, 2.57) | 0.22 | 0.05 | 62 |
|              | Overall    |          | 5           | 1.61 (0.96, 2.70) | 0.07 | <0.01 | 68 |
| GG vs AA     | Ethnic     | Caucasian | 3           | 1.03 (0.71, 1.49) | 0.87 | 0.99 | 0  |
|              | Overall    |          | 4           | 1.16 (0.84, 1.60) | 0.37 | 0.39 | 3  |
| GA vs AA     | Ethnic     | Caucasian | 3           | 1.10 (0.78, 1.55) | 0.58 | 0.8  | 0  |
|              | Overall    |          | 4           | 1.20 (0.90, 1.58) | 0.21 | 0.21 | 32 |
| G vs A       | Ethnic     | Caucasian | 3           | 1.01 (0.84, 1.20) | 0.934 | 0.99 | 0  |
|              | Overall    |          | 4           | 1.04 (0.69, 1.56) | 0.87 | <0.01 | 75 |

AMD age-related macular degeneration, OR odds ratio, CI confidence interval

Fig. 2 Forest plot of the association between genetic effects of rs11200638 polymorphism and anti-VEGF treatment of exudative AMD
susceptibility to AMD, especially the neovascular type in Caucasian and Asian populations [12–16]. In addition, sensitivity analysis was conducted by removing one study at a time, and it showed similar and stable results, thus indicating that the results of the present meta-analysis were relatively robust. We used meta regression to analyze the heterogeneity of GG + GA vs AA genotype. We found that the several variables (the year, N, ethnicity and intervention) were not heterogeneous factors, the main research variables have little effect on the result of meta-regression. Additionally, the shapes of the funnel plots and the results of Egger’s test did not reveal obvious publication bias in this meta-analysis.

ARMS2 polymorphism rs10490924 (A69S) and HTRA1 polymorphism rs11200638 are usually show very similar genotypic distribution. Hu et al. reported significant association between A69S polymorphism rs10490924 and anti-angiogenesis treatment response [26], but present study found no significant pharmacogenetic association with HTRA1 rs11200638. This discrepancy may be caused by following reasons that there were 12 studies included in Hu et al. However, the number of included studies was much less than Hu et al, only 5 studies meet the inclusion criteria in present study. More studies are needed to further prove the conclusion of present study, especially well-designed and high quality prospective intervention studies. In addition, the clinical measures of response to anti-VEGF therapy not only including mean VA, but also the degree of anatomical response (fluid on OCT or FA, retinal thickness, change in total foveal thickness, change in lesion size). Both Hu et al. and this study were only focused on the VA change in pharmacogenetic association. It is not difficult to assume the ARMS2 polymorphism rs10490924 (A69S) and HTRA1 polymorphism rs11200638 may have consistence in other outcome indicators for pharmacogenetic association.

To minimize the bias of our research, we first searched in PubMed, Web of Science, and Embase with no limitations on language, and the studies had to be published in peer-reviewed journals; second, we collected data without ethnicity; and third, we assessed the quality of all of the studies using the NOS, and all of them showed high scores of 7–9. In order to improve the power of our study, we tried to ask original studies for data of odds ratios and continuous variable as well. Heterogeneity is a potential influence that might affect the results of the meta-analysis. However, no significant heterogeneity was observed in the overall population analysis of GG vs AA, GA vs AA, GG + GA vs AA, and G vs A, while in the subgroup analysis was based on ethnicity, heterogeneity was still not existed in the Caucasian population when performing comparisons for all genetic models.
Fig. 4 Results of sensitivity analysis in all genotype model

Fig. 5 Results of meta-regression to analyze the heterogeneity of GG + GA vs AA genotype
Despite our rigorous methodology, some limitations of the current study should not be ignored. First, we cannot completely exclude publication bias by asymmetry plots because the number of included studies was insufficient. Second, the included studies were given adequate definition of positive/negative response. However, the criteria for positive/negative therapeutic response were various among studies although the measures of the response to treatment were just based on VA. In addition, treatment protocol, follow-up period, and study design is various. The underlying heterogeneity in treatment response can’t be completely ignored even though no significant heterogeneity was observed. Third, because of the complex nature of exudative AMD, many factors, including lifestyle, and other polymorphic susceptibility genes that also influence therapeutic outcomes, could not be completely excluded, so it is unsuitable to consider the HTRA1 gene definitely having nothing to do with exudative AMD treatment response. Fourth, the definition of response and the study endpoint were only changes in VA. Changes in central retinal thickness and maximum lesion thickness from baseline were also important treatment outcomes because anti-VEGF treatment could reduce the swelling of the central retina, which would decrease the central retinal thickness and be beneficial to VA improvement. However, studies included in this meta-analysis failed to find out any associations between these two important treatment outcomes and the genetic variants. Fifth, the number of studies included was limited. In addition, because some of the studies have insufficient available data to estimate ORs and its 95% CI [23–28], and two of them showed significant associations between the genetic variants of rs11200638 and patient response [27, 29], they were not included, and the conclusions must be validated by further studies. Finally, although all of studies included were of high quality, a limitation of these studies was that the non-randomized study design was used.

Despite these limitations, this study might be the first meta-analytic review evaluating the associations between polymorphism rs11200638 in the HTRA1 gene and the response to treatment of exudative AMD based on observational studies. No statistically significant pharmacogenetic associations were found between anti-VEGF treatment for exudative AMD and different genotypes in the HTRA1 gene in our meta-analyses. However, it seemed slightly early to draw a conclusion based on limited numbers of studies available so far, especially only studies providing sufficient available data to estimate values of ORs. Future research, especially well-designed and high quality randomized, controlled trials or interventional studies, are highly desirable to enable more precise estimates and better understanding of the relationship between polymorphism rs11200638 in the HTRA1 gene and responses to anti-angiogenesis treatment for exudative AMD.

Conclusions
In conclusion, our meta-analysis indicated that there was no association between the polymorphism rs11200638 in HTRA1 gene and response to anti-VEGF treatment of exudative AMD. However, more studies are needed to further prove the conclusion of present study, especially well-designed and high quality randomised controlled trials or intervention studies.

Abbreviations
AMD: Age related macular degeneration; ARMS2: Age-related maculopathy susceptibility 2; CFH: Complement factor H; CI: Confidence intervals; CNV: Choroidal neovascularization; HTRA1: High temperature requirement factor A1; HWEL: Hardy-Weinberg equilibrium; NOS: Newcastle-Ottawa Scale; OR: Odds ratios; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RPE: Retinal pigment epithelium; SNPs: Single nucleotide polymorphisms; VA: Visual acuity; VEGF: Vascular endothelial growth factor; VEGFA: Vascular endothelial growth factor A; VEGFR2: Vascular endothelial growth factor receptor 2; vs: Versus

Acknowledgements
None.

Funding
This study was partly supported by the Project of the National Natural Science Funds of China (No. 81371040), and the Shanghai Pujiang Program (No. 15PJD028).

Availability of data and materials
The datasets supporting the conclusions of this article has been shared in the Figures and Tables. In addition, the results from search strategies for databases, PRISMA Checklist, and NOS checklist can be found as supplementary file to this article.

Authors’ contributions
ZYW, YLZ, LL and CLC and made substantial contributions to conception and design of this study; YLZ, CLC, YT, and YXW made substantial contributions to acquisition of data; analysis and interpretation of data; YLZ, CLC, LL and XLF drafted the manuscript and revised it critically for important intellectual content and agreed to be accountable for all aspects of the work.

Competing interests
The funding organizations had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Not applicable.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Ophthalmology, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. 2Department of Ophthalmology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. 3Department of Ophthalmology, Shanghai 200011. China. 4Department of Ophthalmology, Shengli Oilfield Central Hospital, Dongying, Shandong, China. 5Department of Ophthalmology, Shanghai Eye Hospital, Shanghai, China.
References
1. de Jong PT. Age-related macular degeneration. N Engl J Med. 2006;355(14):1474–85.
2. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291(15):1900–1.
3. Shahry BS. Genetic diversity and medicinal drug response in eye care. Graefe's Archive for Clinical and Experimental Ophthalmology 2010; 248(8):1057–1061.
4. Chakravarty U. Age related macular degeneration. BMJ (Clinical research ed). 2006;333(7574):869–70.
5. Haddad S, Chen CA, Santangelo SL, Seddon JM. The genetics of age-related macular degeneration: a review of progress to date. Surv Ophthalmol. 2006;51(4):316–63.
6. Priya RR, Chew EY, Swaroop A. Genetic studies of age-related macular degeneration: lessons, challenges, and opportunities for disease management. Ophthalmology. 2012;119(12):2526–36.
7. Seddon JM, Cote J, Page WF, Aggen SH, Neale MC. The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. Archives of ophthalmology (Chicago, Ill.). 1960; 2005;123(3):321–27.
8. Despriet DD, Klaver CC, Witterman JC, Bergen AA, Kardys L, De Maat MP, et al. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA. 2006;296(3):301–9.
9. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, Spencer KL, Kwan SY, Nouredine M, Gilbert JR, et al. Complement factor H variant increases the risk of the risk of age-related macular degeneration. Science (New York, NY) 2005; 308(5720):419–421.
10. Tong Y, Liao J, Zhang Y, Zhou J, Zhang H, Mao M. LOC387715/HTRA1 gene polymorphisms and susceptibility to age-related macular degeneration: a HuGe review and meta-analysis. Mol Vis. 2010;16:1984–90.
11. Jakobsdottir JC, Conley YP, Weeks DE, Mah TS, Ferrell RE, Gorin MB. Susceptibility genes for age-related maculopathy on chromosome 1q26. Am J Hum Genet. 2005;77(3):389–407.
12. Yang Z, Camp NJ, Sun H, Tong Z, Gibbs D, Sun H, Tong Z, Gibbs D, Cameron DJ, Chen H, Zhao Y, Pearson E, Li X et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science (New York, NY) 2006; 314(5801):992–993.
13. Devan A, Liu M, Hartman S, Zhang SS, Liu DT, Zhao C, Tam PC, Chan WM, Lam DS, Snyder M et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science (New York, NY) 2006; 314(5801):989–992.
14. Sobrin L, Reynolds R, Yu Y, Fagerness J, Leveziel N, Bernstein PS, Souied EH, Daly MJ, Seddon JM. ARMS2/HTRA1 locus can confer differential susceptibility to the advanced subtypes of age-related macular degeneration. American journal of ophthalmology. 2011;151(2):345–352.e343.
15. Chen W, Xu W, Tao Q, Liu J, Li X, Gan X, et al. Meta-analysis of the association of the HTRA1 polymorphisms with the risk of age-related macular degeneration. Exp Eye Res. 2009;89(3):292–300.
16. Tuo J, Ross RJ, Reed GF, Yan Q, Wang JJ, Bojankowski CM, et al. The HTRA1 promoter polymorphism, smoking, and age-related macular degeneration in multiple case-control samples. Ophthalmology. 2008;115(11):1891–8.
17. Ding X, Patel M, Chan CC. Molecular pathology of age-related macular degeneration. Prog Retin eye res. Progress in retinal and eye research. 2009; 2009;28(1):1–18.
18. Zhang L, Lim SL, Du H, Zhang M, Kozak I, Hannum G, et al. High temperature requirement factor A1 (HTRA1) gene regulates angiogenesis through transforming growth factor-beta family member growth differentiation factor 6. J Biol Chem. 2012;287(2):1520–6.
19. Martin DF, Maguire MG, Ying GS, Gradstein JA, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–908.
20. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009, 116(11):57–65.e5.
21. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–31.
22. Hermann MM, van Asten F, Muether PS, Smalhodicz D, Lichtner P, Hoyng CB, et al. Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration. Ophthalmology. 2014;121(4):905–10.
23. Park UC, Shin JY, McCarthy LC, Kim SJ, Park JH, Chung H, et al. Pharmacogenomic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients. Mol Vis. 2014;20:1680–94.
24. Dedania VS, Grob S, Zhang K, Bakri SJ. Pharmacogenomics of response to anti-VEGF therapy in exudative age-related macular degeneration. Retina (Philadelphia, Pa) 2015; 35(3):381–91.
25. Chen G, Tzekov R, Li W, Jiang F, Mao S, Tong Y. Pharmacogenomics of complement factor H Y402H polymorphism and treatment of Neovascular AMD with anti-VEGF agents: a meta-analysis. Sci Rep. 2015;5:14517.
26. Hu Z, Xie P, Ding Y, Yuan D, Liu Q. Association between variants A69S in ARMS2 gene and response to treatment of exudative AMD: a meta-analysis. Br J Ophthalmol. 2015;99(5):593–8.
27. Tian J, Qin X, Fang K, Chen Q, Hou J, Li J, et al. Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population. Pharmacogenomics. 2012; 13(9):779–87.
28. Kloeckener-Gruissim B, Barthelmes D, Labs S, Schindler C, Kurz-Levin M, Michels S, et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest Ophthalmol Vis Sci. 2012;53(7):4694–702.
29. Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Craniomaxillo-Facial Surgery. 2011;39(2):191–2.
30. Cota GF, de Sousa MR, Fereguetti TO, Rabello A. Efficacy of anti-lesithin therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison. PLoS Negl Trop Dis. 2013;7(5):e2195.
31. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003;327(7414):557–60.
32. Ioannidis JP, Patsopoulos NA, Evangelou E. Heterogeneity in meta-analyses of genome-wide association studies. PLoS One. 2007;2(9):e841.
33. Pickup JC, Reznik Y, Sutton AJ. Glycemic control during continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: individual patient data meta-analysis and meta-regression of randomized controlled trials. Diabetes Care. 2017;40(5):715–22.
34. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997, n(7109):629–634.
35. Ziegler A, Van Steen K, Wellek S. Investigating Hardy-Weinberg equilibrium in case-control or cohort studies or meta-analysis. Breast Cancer Res Treat. 2011;128(1):197–201.
36. McKibbin M, Ali M, Bansal S, Baxter PD, West K, Williams G, et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br J Ophthalmol. 2012;96(2):208–12.
37. Ollin A, Hadley D, Chang W, Ho AC, Brown G, Kaiser RS, Regillo CD, Godshalk AN, Lier A, Kaderli B et al. Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration. Retina (Philadelphia, Pa) 2012, 32(1):4–9.
38. Abedi F, Wickremasinghe S, Richardson AJ, Islam AF, Guymer RH, Baird PN. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. Ophthalmology. 2013;120(8):1641–8.
39. Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Callanan DG, et al. Pharmacogenetics for genes associated with age-related macular degeneration in the comparison of AMD treatments trials (CATT). Ophthalmology. 2013;120(3):593–9.